Back
Fulcrum Therapeutics Quote, Financials, Valuation and Earnings
"This Changes Everything" - Trump Hands Millions Massive IRS Gift
Learn More Here
Sell
47
FULC
Fulcrum Therapeutics
Last Price:
3.32
Seasonality Move:
67.13%
7 Day Trial
ALL ACCESS PASS
$
7
Trump's IRS Hands Massive 'Victory Gift' To 401K Owners
Shield your IRA, 401(k) and pension savings from this coming anti-Trump backlash.Fulcrum Therapeutics Price Quote
$3.32
-0.25 (-7%)
(Updated: November 14, 2024 at 5:55 PM ET)
Fulcrum Therapeutics Key Stats
Sell
47
Fulcrum Therapeutics (FULC)
is a Sell
Day range:
$3.52 - $3.94
52-week range:
$2.87 - $13.70
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
0.83%
Volume:
870.1K
Avg. volume:
688K
1-year change:
2.88%
Market cap:
$227.8M
Revenue:
$2.8M
EPS:
$-0.35
How Much Does Fulcrum Therapeutics Make?
Data Unavailable
Is Fulcrum Therapeutics Growing As A Company?
-
What Is Fulcrum Therapeutics's Growth Rate Quarterly?
Quarterly YoY revenue growth is 89.91% -
What Is Fulcrum Therapeutics's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Fulcrum Therapeutics Stock Price Performance
-
Did Fulcrum Therapeutics Stock Go Up Last Month?
Fulcrum Therapeutics share price went up by 2.59% last month -
Did FULC's Share Price Rise Over The Last Year?
FULC share price rose by 2.88% over the past 1 year
What Is Fulcrum Therapeutics 52-Week High & Low?
-
What Is Fulcrum Therapeutics’s 52-Week High Share Price?
Fulcrum Therapeutics has traded as high as $13.70 over the past 52 weeks -
What Is Fulcrum Therapeutics’s 52-Week Low Share Price?
Fulcrum Therapeutics has traded as low as $2.87 over the past 52 weeks
Fulcrum Therapeutics Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Fulcrum Therapeutics?
-
How Much Debt Does Fulcrum Therapeutics Have?
Total long term debt quarterly is $0 -
How Much Cash Does Fulcrum Therapeutics Have?
Cash and short term investments quarterly total is $273.8M -
What Is Fulcrum Therapeutics’s Book Value Per Share?
Book value per share is 4.40
Is Fulcrum Therapeutics Cash Flow Positive?
-
What Is FULC Cash Flow From Operations?
Cash flow from operations (TTM) is -$12.4M -
What Is Fulcrum Therapeutics’s Cash Flow From Financing?
Cash flow from financing (TTM) is $2.3M -
What Is Fulcrum Therapeutics’s Cash Flow From Investing?
Cash flow from investing (TTM) is $63M
Fulcrum Therapeutics Return On Invested Capital
-
Is Management Doing A Good Job?
FULC return on invested capital is -8.07% -
What Is Fulcrum Therapeutics Return On Assets?
ROA measures how assets are converting to revenues and is -7.42% -
What Is FULC Return On Equity?
ROE is a measure of profitability and is -8.07%
Fulcrum Therapeutics Earnings Date & Stock Price
-
What Is Fulcrum Therapeutics's Stock Price Today?
A single share of FULC can be purchased today for 3.57 -
What Is Fulcrum Therapeutics’s Stock Symbol?
Fulcrum Therapeutics trades on the nasdaq under the ticker symbol: FULC -
When Is Fulcrum Therapeutics’s Next Earnings Date?
The next quarterly earnings date for Fulcrum Therapeutics is scheduled on February 27, 2025 -
When Is FULC's next ex-dividend date?
Fulcrum Therapeutics's next ex-dividend date is May 7, 2020 -
How To Buy Fulcrum Therapeutics Stock?
You can buy Fulcrum Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Fulcrum Therapeutics Competitors
-
Who Are Fulcrum Therapeutics's Competitors?
Below is a list of companies who compete with Fulcrum Therapeutics or are related in some way:
Fulcrum Therapeutics Dividend Yield
-
What Is FULC Dividend Yield?
Fulcrum Therapeutics’s dividend yield currently is 0% -
What Is Fulcrum Therapeutics’s Payout Ratio?
Fulcrum Therapeutics’s payout ratio is 0% -
When Did Fulcrum Therapeutics Last Pay A Dividend?
The latest dividend pay date is November 15, 2024 -
What Is Fulcrum Therapeutics’s Dividend Per Share?
Fulcrum Therapeutics pays a dividend of $0.00 per share
Fulcrum Therapeutics Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 0% | 1.63% |
| Revenue: | 8990.91% | -100% |
Analyst Recommendations
| Buy Recommendations: | 1 |
|---|---|
| Hold Recommendations: | 5 |
| Sell Recommendations: | 0 |
| Price Target: | 5.29 |
| Upside from Last Price: | 48.06% |